An open-label, non-comparative, single centre, phase II exploratory study to assess the efficacy of a flexible dose of oral Quetiapine Fumarate tablets (300-800 mg) in the treatment of Borderline Personalisty Disorder in adult patients receiving treatment for 12 weeks.
Study identifier:D1449L00006
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open-label, non-comparative, single centre, phase II exploratory study to assess the efficacy of a flexible dose of oral Quetiapine Fumarate tablets (300-800 mg) in the treatment of Borderline Personalisty Disorder in adult patients receiving treatment for 12 weeks.
Medical condition
schizophrenia
Phase
Phase 2
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Feb 2005
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
-
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
